Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections
Open Access
- 1 June 1988
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 32 (6) , 802-806
- https://doi.org/10.1128/aac.32.6.802
Abstract
To investigate whether 10 days of rifampin-trimethoprim (RIF-TMP) or 6 weeks of sulfamethoxazole-trimethoprim (SMX-TMP) would decrease the relapse rate in patients with acute uncomplicated upper urinary tract infections in comparison with 10 days of SMX-TMP, we randomized 189 patients to receive RIF-TMP or SMX-TMP in a ratio of 1:2. After the site of infection was established by the antibody-coated bacterium (ACB) test, patients with upper-tract infections who received SMX-TMP were again randomized and received either a total of 6 weeks or 10 days of therapy. All patients who received RIF-TMP were treated for 10 days. Clinical and microbiological evaluations were repeated at 2 and 6 weeks posttreatment. Eighty-five patients (54 ACB positive) received 10 days of RIF-TMP, 71 patients (45 ACB positive) received 10 days of SMX-TMP, and 18 patients (18 ACB positive) received 6 weeks of SMX-TMP. The overall recurrence rates in patients who received 10 days of therapy were 32% for RIF-TMP and 23% for SMX-TMP (P = 0.13). There were 12 (14%) relapses in the RIF-TMP group compared with 2 (3%) relapses in the SMX-TMP group (P = 0.01). In patients with upper-tract infections, the relapse rates were not statistically significantly different (P = 0.13). There were two (11%) recurrences (one relapse and one reinfection) in the 6-week treatment group. This 6% relapse rate was not different from the 4% relapse rate observed in patients with upper-tract infections who received 10 days of SMX-TMP. The number of patients who discontinued treatment because of an adverse effect in the 6-week SMX-TMP treatment group was significantly greater than those in the 10-day SMX-TMP treatment group (P=0.003) and the RIF-TMP treatment group (P=0.05). Ten days of SMX-TMP was as effective as 6 weeks of SMP-TMP or 10 days of RIF-TMP in the treatment of uncomplicated upper urinary tract infections and caused the fewest untoward effects.This publication has 28 references indexed in Scilit:
- Use of Rifampin for the Treatment of Urinary Tract InfectionsClinical Infectious Diseases, 1983
- Rifaprim in urinary tract infection: A comparison with co-trimoxazoleJournal of Antimicrobial Chemotherapy, 1983
- Diagnosis of Coliform Infection in Acutely Dysuric WomenNew England Journal of Medicine, 1982
- Causes of the Acute Urethral Syndrome in WomenNew England Journal of Medicine, 1980
- Orange Contact Lenses from RifampinNew England Journal of Medicine, 1979
- Double-Blind Multicenter Trial of a Rifampicin–Trimethoprim Combination and Rifampicin Alone in Urinary Tract InfectionsChemotherapy, 1979
- Efficacy of Single-Dose and Conventional Amoxicillin Therapy in Urinary-Tract Infection Localized by the Antibody-Coated Bacteria TechnicNew England Journal of Medicine, 1978
- Role of Antibody-Coated Bacteria in the Management of Urinary Tract InfectionsSouthern Medical Journal, 1977
- The interactions between rifampicin and trimethoprim: an in vitro studyJournal of Antimicrobial Chemotherapy, 1977
- Kinetic studies on the combination rifampicin-trimethoprim in manJournal of Antimicrobial Chemotherapy, 1976